Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

It is a Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer. It is divided into two parts: an induction period of 6 cycles of 3 weeks each cycle of Pembrolizumab+Cabazitaxel+Carboplatino and a maintenance phase of 15 cycles of 6 weeks each cycle of Pembrolizumab.

Trial Details

NCT ID
NCT05563558
Phase
PHASE2
Sponsor
Fundacion Oncosur
Status
RECRUITING
Cancer Type
Neuroendocrine Prostate Cancer
Interventions
  • Pembrolizumab
  • Carboplatin
  • Cabazitaxel
Locations (sample)
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Male participants who are at least 18 years of age on the day of signing informed consent
  • Histologically confirmed diagnosis of adenocarcinoma and/or neuroendocrine carcinoma of the prostate will be enrolled in this study
  • Presence of metastatic disease documented on imaging studies (bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI) scans
  • At least one of the following Aggressive Variant Prostate Cancer (AVPC) Criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Neuroendocrine Prostate Cancer Trials on Trialify →